TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Prognostic Significance of Fibrosis Detection in Ischemic and Non-ischemic Cardiomyopathy
Brief Summary: The presence of scar within heart muscle can act as a substrate for abnormal rhythm problems and lead to the developement of heart failure

Clinical significance Correlation with biomarkers and genetic markers


Options:
A: Arm Label: Olmesartan medoxomil; Type: ACTIVE_COMPARATOR; Interventions: Drug: olmesartan medoxomil | Arm Label: Standard therapy; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: olmesartan medoxomil; Assigned to Arm(s): Olmesartan medoxomil
B: Arm Label: Aggrenox, Clopidogrel placebo, Micardis; Type: PLACEBO_COMPARATOR; Interventions: Drug: Aggrenox, Drug: Clopidogrel placebo, Drug: Micardis | Arm Label: Aggrenox placebo, clopidogrel,, Micardis; Type: PLACEBO_COMPARATOR; Interventions: Drug: Micardis, Drug: Aggrenox placebo, Drug: Clopidogrel | Arm Label: Aggrenox, clop placebo, micardis placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Aggrenox, Drug: Clopidogrel placebo, Drug: Micardis placebo | Arm Label: Aggrenox plcebo, clop, micardis placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Aggrenox placebo, Drug: Clopidogrel, Drug: Micardis placebo | Intervention Type: DRUG; Name: Aggrenox; Assigned to Arm(s): Aggrenox, Clopidogrel placebo, Micardis | Intervention Type: DRUG; Name: Aggrenox; Assigned to Arm(s): Aggrenox, clop placebo, micardis placebo | Intervention Type: DRUG; Name: Clopidogrel placebo; Assigned to Arm(s): Aggrenox, Clopidogrel placebo, Micardis | Intervention Type: DRUG; Name: Clopidogrel placebo; Assigned to Arm(s): Aggrenox, clop placebo, micardis placebo | Intervention Type: DRUG; Name: Micardis; Assigned to Arm(s): Aggrenox, Clopidogrel placebo, Micardis | Intervention Type: DRUG; Name: Micardis; Assigned to Arm(s): Aggrenox placebo, clopidogrel,, Micardis | Intervention Type: DRUG; Name: Aggrenox placebo; Assigned to Arm(s): Aggrenox placebo, clopidogrel,, Micardis | Intervention Type: DRUG; Name: Aggrenox placebo; Assigned to Arm(s): Aggrenox plcebo, clop, micardis placebo | Intervention Type: DRUG; Name: Clopidogrel; Assigned to Arm(s): Aggrenox placebo, clopidogrel,, Micardis | Intervention Type: DRUG; Name: Clopidogrel; Assigned to Arm(s): Aggrenox plcebo, clop, micardis placebo | Intervention Type: DRUG; Name: Micardis placebo; Assigned to Arm(s): Aggrenox, clop placebo, micardis placebo | Intervention Type: DRUG; Name: Micardis placebo; Assigned to Arm(s): Aggrenox plcebo, clop, micardis placebo
C: Arm Label: Myocardial fibrosis, outcomes; Type: N/A; Interventions: N/A
D: Arm Label: Initial presentation of coronary disease - Stable angina; Type: N/A; Interventions: N/A | Arm Label: Initial presentation of coronary disease - ACS; Type: N/A; Interventions: N/A | Arm Label: Initial presentation of coronary disease - Coronary death; Type: N/A; Interventions: N/A | Arm Label: Initial presentation of coronary disease - None; Type: N/A; Interventions: N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Prospective, Multicenter, Single Blind, Randomized, Controlled Trial Comparing the Lutonix Catheter vs. Standard Balloon Angioplasty for Treatment of Femoropopliteal Arteries With and Without Stenting.
Brief Summary: The purpose of the study is to assess the safety and efficacy of the Lutonix Catheter for treatment of stenosis of the femoropopliteal arteries by direct comparison to standard balloon angioplasty.


Options:
A: Arm Label: Lutonix Catheter; Type: EXPERIMENTAL; Interventions: Device: Lutonix Catheter | Arm Label: Standard uncoated Balloon Angioplasty Catheter; Type: ACTIVE_COMPARATOR; Interventions: Device: Standard uncoated Balloon Angioplasty Catheter | Intervention Type: DEVICE; Name: Lutonix Catheter; Assigned to Arm(s): Lutonix Catheter | Intervention Type: DEVICE; Name: Standard uncoated Balloon Angioplasty Catheter; Assigned to Arm(s): Standard uncoated Balloon Angioplasty Catheter
B: Arm Label: Drug-Coated Balloon (DCB); Type: EXPERIMENTAL; Interventions: Device: Drug-Coated Balloon (DCB) | Arm Label: Standard PTA; Type: ACTIVE_COMPARATOR; Interventions: Device: PTA Balloon: Balloon Angioplasty | Intervention Type: DEVICE; Name: Drug-Coated Balloon (DCB); Assigned to Arm(s): Drug-Coated Balloon (DCB) | Intervention Type: DEVICE; Name: PTA Balloon: Balloon Angioplasty; Assigned to Arm(s): Standard PTA
C: Arm Label: Stent; Type: EXPERIMENTAL; Interventions: Device: Zilver® PTX™ Stent | Intervention Type: DEVICE; Name: Zilver® PTX™ Stent; Assigned to Arm(s): Stent
D: Intervention Type: DRUG; Name: Balloon Angioplasty with or without drug administration; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Heat Loss Prevention in Delivery Room: a Prospective, Randomised, Controlled Trial of Polyethylene Caps in Very Preterm Infants
Brief Summary: It is apparent that the head of a preterm infant should not be left uncovered, however it remains unclear whether covering the head of a preterm baby with plastic wrapping is effective in preventing heat loss.

We conducted a prospective, randomised, controlled trial in very preterm infants to evaluate if a polyethylene cap prevents heat loss after delivery better than polyethylene occlusive wrapping and conventional drying. Furthermore, we assessed body temperature 1 hour after admission to Neonatal Intensive Care Unit (NICU) to evaluate whether the polyethylene cap prevents postnatal heat loss.


Options:
A: Arm Label: A; Type: EXPERIMENTAL; Interventions: Behavioral: TK as soon as possible within 24 hours after birth | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Other: Conventional care | Intervention Type: BEHAVIORAL; Name: TK as soon as possible within 24 hours after birth; Assigned to Arm(s): A | Intervention Type: OTHER; Name: Conventional care; Assigned to Arm(s): B
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Device: Polyethylene occlusive skin wrap | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Polyethylene occlusive skin wrap; Assigned to Arm(s): 1
C: Arm Label: Total body polyethylene wrap (body plus head); Type: EXPERIMENTAL; Interventions: Device: Polyethylene wrap | Arm Label: Polyethylene wrap (body); Type: ACTIVE_COMPARATOR; Interventions: Device: Polyethylene wrap | Intervention Type: DEVICE; Name: Polyethylene wrap; Assigned to Arm(s): Total body polyethylene wrap (body plus head) | Intervention Type: DEVICE; Name: Polyethylene wrap; Assigned to Arm(s): Polyethylene wrap (body)
D: Arm Label: cap; Type: EXPERIMENTAL; Interventions: Device: Polyethylene cap | Arm Label: wrap; Type: ACTIVE_COMPARATOR; Interventions: Device: Polyethylene wrap | Arm Label: conventional group; Type: OTHER; Interventions: Other: conventional treatment | Intervention Type: DEVICE; Name: Polyethylene cap; Assigned to Arm(s): cap | Intervention Type: DEVICE; Name: Polyethylene wrap; Assigned to Arm(s): wrap | Intervention Type: OTHER; Name: conventional treatment; Assigned to Arm(s): conventional group

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized, Placebo-controlled, Double-blind, Multi-center Study to Evaluate the Safety and Efficacy of Ciprofloxacin Inhale Compared to Placebo in Patients With Non-cystic Fibrosis Bronchiectasis
Brief Summary: The purpose of this study is to find out if bacterial load in the airways can be reduced after inhalation of ciprofloxacin for 28 days.


Options:
A: Arm Label: Ciprofloxacin DPI 28 Days on/off (Cipro 28); Type: EXPERIMENTAL; Interventions: Drug: Ciprofloxacin DPI (BAYQ3939) | Arm Label: Ciprofloxacin DPI 14 Days on/off (Cipro 14); Type: EXPERIMENTAL; Interventions: Drug: Ciprofloxacin DPI (BAYQ3939) | Arm Label: Placebo 28 Days on/off (Placebo 28); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Placebo 14 Days on/off (Placebo 14); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Ciprofloxacin DPI (BAYQ3939); Assigned to Arm(s): Ciprofloxacin DPI 14 Days on/off (Cipro 14), Ciprofloxacin DPI 28 Days on/off (Cipro 28) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo 14 Days on/off (Placebo 14), Placebo 28 Days on/off (Placebo 28)
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Gentamicin | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Saline | Intervention Type: DRUG; Name: Gentamicin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Saline; Assigned to Arm(s): 2
C: Arm Label: AZLI-AZLI; Type: EXPERIMENTAL; Interventions: Drug: AZLI | Arm Label: Placebo-AZLI; Type: PLACEBO_COMPARATOR; Interventions: Drug: AZLI, Drug: Placebo | Intervention Type: DRUG; Name: AZLI; Assigned to Arm(s): AZLI-AZLI, Placebo-AZLI | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo-AZLI
D: Arm Label: Ciprofloxacin Inhale (BAYQ3939); Type: EXPERIMENTAL; Interventions: Drug: Ciprofloxacin (Cipro, BAYQ3939) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Ciprofloxacin (Cipro, BAYQ3939); Assigned to Arm(s): Ciprofloxacin Inhale (BAYQ3939) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized, Placebo-controlled, Double-blind, Multi-center Study to Evaluate the Safety and Efficacy of Ciprofloxacin Inhale Compared to Placebo in Patients With Non-cystic Fibrosis Bronchiectasis
Brief Summary: The purpose of this study is to find out if bacterial load in the airways can be reduced after inhalation of ciprofloxacin for 28 days.


Options:
A: Arm Label: AZLI-AZLI; Type: EXPERIMENTAL; Interventions: Drug: AZLI | Arm Label: Placebo-AZLI; Type: PLACEBO_COMPARATOR; Interventions: Drug: AZLI, Drug: Placebo | Intervention Type: DRUG; Name: AZLI; Assigned to Arm(s): AZLI-AZLI, Placebo-AZLI | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo-AZLI
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Gentamicin | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Saline | Intervention Type: DRUG; Name: Gentamicin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Saline; Assigned to Arm(s): 2
C: Arm Label: Azithromycin treatment 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Azithromycin | Arm Label: Placebo 2; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Azithromycin; Assigned to Arm(s): Azithromycin treatment 1 | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo 2
D: Arm Label: Ciprofloxacin Inhale (BAYQ3939); Type: EXPERIMENTAL; Interventions: Drug: Ciprofloxacin (Cipro, BAYQ3939) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Ciprofloxacin (Cipro, BAYQ3939); Assigned to Arm(s): Ciprofloxacin Inhale (BAYQ3939) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized, Placebo-controlled, Double-blind, Multi-center Study to Evaluate the Safety and Efficacy of Ciprofloxacin Inhale Compared to Placebo in Patients With Non-cystic Fibrosis Bronchiectasis
Brief Summary: The purpose of this study is to find out if bacterial load in the airways can be reduced after inhalation of ciprofloxacin for 28 days.


Options:
A: Arm Label: Ciprofloxacin Inhale (BAYQ3939); Type: EXPERIMENTAL; Interventions: Drug: Ciprofloxacin (Cipro, BAYQ3939) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Ciprofloxacin (Cipro, BAYQ3939); Assigned to Arm(s): Ciprofloxacin Inhale (BAYQ3939) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: AZLI-AZLI; Type: EXPERIMENTAL; Interventions: Drug: AZLI | Arm Label: Placebo-AZLI; Type: PLACEBO_COMPARATOR; Interventions: Drug: AZLI, Drug: Placebo | Intervention Type: DRUG; Name: AZLI; Assigned to Arm(s): AZLI-AZLI, Placebo-AZLI | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo-AZLI
C: Arm Label: Azithromycin treatment 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Azithromycin | Arm Label: Placebo 2; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Azithromycin; Assigned to Arm(s): Azithromycin treatment 1 | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo 2
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Gentamicin | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Saline | Intervention Type: DRUG; Name: Gentamicin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Saline; Assigned to Arm(s): 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Early Versus Standard Drainage Removal After Pancreatic Resections: Results of a Prospective Randomized Clinical Trial
Brief Summary: Despite a substantial decrease in postoperative mortality, morbidity after pancreatic resections is still high, even at high-volume centers. It has been recently suggested that early removal of postoperative drainages is associated to a decreased rate of intra-abdominal complications, with particular regard to pancreatic fistula. Furthermore, our research group demonstrated that measuring amylase value in drainages (AVD) on postoperative day 1 plays a cardinal role in predicting the developement of abdominal complications, including pancreatic fistula. In particular, patients with an AVD lower than 5000 IU/L in postoperative day 1 were considered at low risk of fistula. Therefore, the investigators designed a randomized prospective trial on early (postoperative day 3) versus standard (postoperative day 5) drainages removal after pancreatic resections in patients at low risk of developing pancreatic fistula (AVD \< 5000 IU/L in postoperative day 1) to test whether drainages "per se" influence postoperative complication rates and to eventually validate a fast-track policy in pancreatic resections.


Options:
A: Arm Label: No Drains; Type: EXPERIMENTAL; Interventions: Procedure: No Drains | Arm Label: Drains; Type: EXPERIMENTAL; Interventions: Procedure: Drains | Intervention Type: PROCEDURE; Name: No Drains; Assigned to Arm(s): No Drains | Intervention Type: PROCEDURE; Name: Drains; Assigned to Arm(s): Drains
B: Arm Label: Standard drainage; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Standard drain removal | Arm Label: Short drainage; Type: EXPERIMENTAL; Interventions: Procedure: Drain removal at D4 | Intervention Type: PROCEDURE; Name: Drain removal at D4; Assigned to Arm(s): Short drainage | Intervention Type: PROCEDURE; Name: Standard drain removal; Assigned to Arm(s): Standard drainage
C: Arm Label: Early drain removal; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Postoperative drain removal | Arm Label: Standard drain removal; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Postoperative drain removal | Intervention Type: PROCEDURE; Name: Postoperative drain removal; Assigned to Arm(s): Early drain removal, Standard drain removal
D: Arm Label: One-layer duct-to-mucosa Group; Type: EXPERIMENTAL; Interventions: Procedure: Modified one-layer duct-to-mucosa Pancreaticojejunostomy | Arm Label: Invagination Group; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Invagination pancreaticojejunostomy | Intervention Type: PROCEDURE; Name: Modified one-layer duct-to-mucosa Pancreaticojejunostomy; Assigned to Arm(s): One-layer duct-to-mucosa Group | Intervention Type: PROCEDURE; Name: Invagination pancreaticojejunostomy; Assigned to Arm(s): Invagination Group

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Early Versus Standard Drainage Removal After Pancreatic Resections: Results of a Prospective Randomized Clinical Trial
Brief Summary: Despite a substantial decrease in postoperative mortality, morbidity after pancreatic resections is still high, even at high-volume centers. It has been recently suggested that early removal of postoperative drainages is associated to a decreased rate of intra-abdominal complications, with particular regard to pancreatic fistula. Furthermore, our research group demonstrated that measuring amylase value in drainages (AVD) on postoperative day 1 plays a cardinal role in predicting the developement of abdominal complications, including pancreatic fistula. In particular, patients with an AVD lower than 5000 IU/L in postoperative day 1 were considered at low risk of fistula. Therefore, the investigators designed a randomized prospective trial on early (postoperative day 3) versus standard (postoperative day 5) drainages removal after pancreatic resections in patients at low risk of developing pancreatic fistula (AVD \< 5000 IU/L in postoperative day 1) to test whether drainages "per se" influence postoperative complication rates and to eventually validate a fast-track policy in pancreatic resections.


Options:
A: Arm Label: SOM230; Type: EXPERIMENTAL; Interventions: Drug: Pasireotide (SOM230) | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Intervention Type: DRUG; Name: Pasireotide (SOM230); Assigned to Arm(s): SOM230 | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): placebo
B: Arm Label: Closed suction drain; Type: ACTIVE_COMPARATOR; Interventions: Procedure: closed suction drain | Arm Label: Closed gravity drain; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Closed gravity drain | Intervention Type: PROCEDURE; Name: Closed gravity drain; Assigned to Arm(s): Closed gravity drain | Intervention Type: PROCEDURE; Name: closed suction drain; Assigned to Arm(s): Closed suction drain
C: Arm Label: No Drains; Type: EXPERIMENTAL; Interventions: Procedure: No Drains | Arm Label: Drains; Type: EXPERIMENTAL; Interventions: Procedure: Drains | Intervention Type: PROCEDURE; Name: No Drains; Assigned to Arm(s): No Drains | Intervention Type: PROCEDURE; Name: Drains; Assigned to Arm(s): Drains
D: Arm Label: Early drain removal; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Postoperative drain removal | Arm Label: Standard drain removal; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Postoperative drain removal | Intervention Type: PROCEDURE; Name: Postoperative drain removal; Assigned to Arm(s): Early drain removal, Standard drain removal

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Citalopram Versus Citalopram Plus Pindolol in Latency of Antidepressant Response Shortening in Major Depressive Disorder
Brief Summary: The purpose of this study is to examine whether the speed of the clinical antidepressant action of citalopram can be accelerated by administering double doses of pindolol (15 mg/day, tid) which presumably should lead to increased 5-HT1A autoreceptor occupancy.


Options:
A: Intervention Type: DRUG; Name: Ebixa (memantine hydrochloride); Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Cipralex (escitalopram); Assigned to Arm(s): N/A
B: Arm Label: Citalopram + placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Pindolol | Arm Label: Citalopram + pindolol; Type: EXPERIMENTAL; Interventions: Drug: Pindolol | Intervention Type: DRUG; Name: Pindolol; Assigned to Arm(s): Citalopram + pindolol, Citalopram + placebo
C: Arm Label: Single Arm; Type: EXPERIMENTAL; Interventions: Drug: Escitalopram | Intervention Type: DRUG; Name: Escitalopram; Assigned to Arm(s): Single Arm
D: Arm Label: 1 Problem Solving Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Problem Solving Therapy | Arm Label: 2. Escitalopram; Type: EXPERIMENTAL; Interventions: Drug: Escitalopram | Arm Label: 3 Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: BEHAVIORAL; Name: Problem Solving Therapy; Assigned to Arm(s): 1 Problem Solving Therapy | Intervention Type: DRUG; Name: Escitalopram; Assigned to Arm(s): 2. Escitalopram | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): 3 Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Preventing Recurrent Vascular Events and Neurological Worsening Through Intensive Organized Case-Management (PREVENTION) Trial
Brief Summary: People who have had a stroke or transient ischemic attack (TIA or "mini-stroke") are at high risk of having another stroke or a heart attack. Conditions like high blood pressure and high cholesterol, along with other lifestyle behaviors (e.g., smoking), substantially increase the risk of stroke and heart disease. Aggressive treatment of these risk factors however, can significantly reduce the chance of another stroke, heart attack or death.

This study will look at different ways to optimize blood pressure and cholesterol levels and educate people about positive lifestyle changes.


Options:
A: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Other: Physician/Pharmacist Collaborative Teams | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Physician/Pharmacist Collaborative Teams; Assigned to Arm(s): Intervention
B: Arm Label: Intensive pharmacist case management; Type: EXPERIMENTAL; Interventions: Drug: Antihypertensive agents and lipid lowering therapy | Arm Label: Usual care; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual Care | Intervention Type: DRUG; Name: Antihypertensive agents and lipid lowering therapy; Assigned to Arm(s): Intensive pharmacist case management | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): Usual care
C: Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Self-management; Type: EXPERIMENTAL; Interventions: Other: Self-monitoring and adjustment of oral anticoagulation | Intervention Type: OTHER; Name: Self-monitoring and adjustment of oral anticoagulation; Assigned to Arm(s): Self-management
D: Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Home Blood Pressure Monitoring Group; Type: EXPERIMENTAL; Interventions: Behavioral: Home Blood Pressure Monitoring | Intervention Type: BEHAVIORAL; Name: Home Blood Pressure Monitoring; Assigned to Arm(s): Home Blood Pressure Monitoring Group

Answer: B